secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evommune, Inc. (EVMN)
CIK:        0002044725
Form:       8-K
Filed at:   2026-07-30T12:01:01+00:00
Accession:  0001193125-26-324972
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evommune doses first patient in Phase 2b trial of EVO756 for migraine prophylaxis
--------------------------------------------------------------------------------

- First patient dosed in Phase 2b trial of MRGPRX2 inhibitor EVO756 for migraine prophylaxis.
- Global, randomized, double-blind, placebo-controlled, dose-ranging trial with ~330 patients over 12 weeks.
- Top-line data expected in 2027; daily doses up to 100 mg being tested.
- EVO756 designed to inhibit three key neuropeptides (PACAP, VIP, Substance P) via MRGPRX2.
- Primary endpoint: mean change from baseline in monthly migraine days (MMD).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2044725/000119312526324972/0001193125-26-324972-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2044725/000119312526324972/evmn-20260731.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-324972

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer